National Cancer Institute Directors (NCID) Meeting 2013

Dr Donato Greco talks to ecancer at the 2013 National Cancer Institute Directors Meeting (NCID 2013) in Lyon about how a diet high in antioxidants, low in fats and red meat can help prevent numerous types of cancer.

Dr Richard Visser talks to ecancer at the 2013 National Cancer Institute Directors Meeting (NCID 2013) in Lyon about the development of the public health system in Aruba and implementing initiatives to involve young people. Dr Visser also discusses Aruba’s methods for treating non-communicable diseases and high obesity rates.

Dr Bhakta Man Shrestha talks to ecancer at the 2013 National Cancer Institute Directors Meeting (NCID 2013) in Lyon about the differences between cancer surgery in Nepal and the west.

Prof David Zaridze talks to ecancer at the 2013 National Cancer Institute Directors Meeting (NCID 2013) in Lyon about programmes and initatives in Russia aimed at reducing lung cancer cases through smoking cessation and prevention. Prof Zaridze cites the drop in smoking in the UK and US after the discovery of its connection with lung cancer as motivation and a model for future work in Russia.

Prof Nise Yamaguchi talks to ecancer at the 2013 National Cancer Institute Directors Meeting (NCID 2013) in Lyon about rates of cancer in Brazil, particularly those caused by obesity and environmental factors. Through collaboration with medical societies across the globe and a defined goal of prevention, there has been reduction in smoking to below 20% and a new push to educate the population on prevention methods.

Dr Peter Johnstone talks to ecancer at the 2013 National Cancer Institute Directors Meeting (NCID 2013) in Lyon about the use of radiotherapy in developed and developing countries. Dr Johnstone discusses how each country must consider a number of factors when looking to improve their radiotherapy treatment guidelines, such as the needs for the cancer population, overall cost, training and maintenance of equipment.

Dr Pierre Hainaut talks to ecancer at the 2013 National Cancer Institute Directors Meeting (NCID 2013) in Lyon about the main risk factors, such as hepatitis, alcohol consumption and metabolic diseases, for liver cancer. Even with a vaccine for hepatitis B, and a developing vaccine for hepatitis C, there is a large question as to whether or not this will provide long-term prevention results. Dr Hainaut stresses that the main research that needs to be completed is on how to implement prevention methods and quickly collect results while monitoring progress.

Dr Leonardo Chavane talks to ecancer at the 2013 National Cancer Institute Directors Meeting (NCID 2013) in Lyon about the international NGO, Jhpiego, that supports the minister of health in Mozambique in running programmes focusing on maternal and child health. In a low resource setting, it is a delicate balance prioritising how to implement prevention programmes for cervical cancer. Dr Chavance discusses the benefits and challenges with using the low cost procedure, Visual Inspection with Acetic Acid, or VIA, which Jhpiego began using in 2009.

Dr Mamadou Diop talks to ecancer at the 2013 National Cancer Institute Directors Meeting (NCID 2013) in Lyon about the logistical and political complications of creating data registries in order to understand the trends in cancer incidence from infectious diseases.

Dr Alajmi Adil Aljarrah talks to ecancer at the 2013 National Cancer Institute Directors Meeting (NCID 2013) in Lyon about recently published data on new, less invasive treatment options of the benign breast disease granulomatous mastitis.

Dr Murat Tuncer talks to ecancer at the 2013 National Cancer Institute Directors Meeting (NCID 2013) in Lyon about the 81 cancer registries in Turkey, one in each city. The centers aim to gather a complete regional picture of incidence in Turkey and highlight needs for screening and prevention.

Prof Anne Merriman talks to ecancer at the 2013 National Cancer Institute Directors Meeting in Lyon about the importance of affordable palliative care, expanding the distribution of prescribed morphine and establishing a strong foundation of educated healthcare workers in countries in Africa.

Dr William Wood talks to ecancer at the 2013 National Cancer Institute Directors Meeting (NCID 2013) in Lyon about clinical trial design and how there is a large need to provide more efficient trial designs. As both low and high income countries are running out of funding for research, clinical trials are under more pressure to achieve results that will significantly improve treatment and lower cost. As a result of this growing challenge, the production of generic versions of drugs is taking longer and prompting trials that investigate if there is measurable difference between generic and branded agents.

Dr Simon Mackay talks to ecancer at the 2013 National Cancer Institute Directors Meeting (NCID 2013) in Lyon about the development of targeted molecules in validated prostate cancer, specifically targeting IKK-alpha.

Dr Edward Trapido talks to ecancer at the 2013 National Cancer Institute Directors Meeting (NCID 2013) in Lyon about the oil spill disaster in 2010 and how many of the long term effects are only now surfacing as factors, such as chemicals used to remove the oil, will have a large impact both on the environment and the health of individuals involved.

Dr Evi Farazi talks to ecancer at the 2013 National Cancer Institute Directors Meeting (NCID 2013) in Lyon about epidemiology in Cyprus and the difficulties of securing funding.

Dr Mireille Guigaz talks to ecancer at the 2013 National Cancer Institute Directors Meeting (NCID 2013) in Lyon about preparing for the growing number of cancer cases and treating non-communicable diseases.

Dr Rajendra Badwe talks to ecancer at the 2013 National Cancer Institute Directors Meeting (NCID 2013) in Lyon about the scientific and social difficulties of introducing new screening measures for cervical and breast cancer in India.

Prof Peter Boyle talks to ecancer at the 2013 National Cancer Institute Directors Meeting (NCID 2013) in Lyon about the goals and history of the meeting.